Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 55 Neoplasms, Plasma Cell 22 Central Nervous System Neoplasms 10 Prostatic Neoplasms 9 Glioblastoma 9 Recurrence 8 Melanoma 8 Brain Neoplasms 8 Neoplasms 7 Gliosarcoma 7 Carcinoma, Non-Small-Cell Lung 7 Sarcoma 6 Leukemia 6 Carcinoma, Hepatocellular 6 Waldenstrom Macroglobulinemia 5 Myeloproliferative Disorders 5 Lung Neoplasms 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Glioma 5 Colorectal Neoplasms 5 Myelodysplastic-Myeloproliferative Diseases 4 Myelodysplastic Syndromes 4 Lymphoma 4 Liver Neoplasms 4 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4 Kidney Neoplasms 4 Carcinoma, Renal Cell 4 Lymphoma, Mantle-Cell 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Myelomonocytic, Chronic 3

Interventions

Mirtazapine 4 Megestrol Acetate 4 nabiximols 1 anamorelin 1 Watchful Waiting 1 Thalidomide 1 Olanzapine 1 Observation 1 Megestrol 1 Infliximab 1 Gemcitabine 1 Flurandrenolone 1 EOM613 1 Dronabinol 1 Dexamethasone 1 Calcium Dobesilate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Anorexia × Thalidomide × Clear all

NCT00379353 2013-02-04

The Effects of Thalidomide on Symptom Clusters

M.D. Anderson Cancer Center

Phase 2 Completed

32 enrolled 14 charts

Anorexia, Fatigue

Data powered by HemOnc (CC BY 4.0) Colophon ⚡